AACR 2015: Proteogenomics and Phosphoproteomics in Cancer: Analysis of the TCGA Tumor Samples

Wednesday, April 22, 2015, 10:00 AM - 12:00 PM
Room 121, Pennsylvania Convention Center, Philadelphia, Pa.

The Cancer Genome Atlas has provided an important foundation for understanding the scope and relationships of genomic alterations in human cancers. The National Cancer Institute recognized that global proteomic characterization of genomically annotated TCGA samples, leveraging recent dramatic improvements in the depth and quantitative capability of mass spectrometry-based proteomics, could provide complementary as well as unique information about cancer biology and signaling that cannot be inferred from genomic analyses alone. This session will present results of the proteomic and phosphoproteomic analyses of breast, colon and ovarian tumor TCGA samples conducted by the Clinical Proteomic Tumor Analysis Consortium. The unique information that global MS-based proteomics provides will be emphasized, together with integrated analysis of the relationships between genomic and proteomic characteristics. The increasing importance of targeted mass spectrometry to develop and apply highly multiplexed thematic panels of quantitative assays to study cancer pathways of interest will also be highlighted.

  • Steven A. Carr. Broad Institute of MIT and Harvard, Cambridge, Mass.
  • Douglas R. Lowy. National Cancer Institute, Bethesda, Md.
  • Daniel C. Liebler. Vanderbilt University, Nashville, Tenn.
  • Philipp Mertins, Broad Institute of MIT and Harvard, Cambridge, Mass.
  • Karin D. Rodland. Pacific Northwest National Laboratory, Richland, Wash.
  • Amanda G. Paulovich. Fred Hutchinson Cancer Research Center, Seattle, Wash.

For more information, please visit the AACR website